TY - JOUR
T1 - Bolus magnesium infusion in humans is associated with predominantly unfavourable changes in platelet aggregation and certain haemostatic factors
AU - Serebruany, Victor L.
AU - Herzog, William R.
AU - Schlossberg, Matthew L.
AU - Gurbel, Paul A.
N1 - Funding Information:
This study was supported by a faculty seed fund of the University of Maryland School of Medicine, grant No. 02390510 and a research grant from Medtronic, Inc. These data have been reported in part during the European Congress of Cardiology (Birmingham, September 1996) and during the American College of Cardiology (Anaheim, March 1997).
PY - 1997/7
Y1 - 1997/7
N2 - The purpose of this study was an attempt to extrapolate favorable observations on the effects of magnesium on platelets and haemostasis from animal models to humans. Intravenous magnesium in the treatment of acute myocardial infarction has been tested in several large clinical trials and remains controversial. The mechanism for the cardioprotective properties of magnesium is unknown. Based on experimental studies, several different hypotheses have been advanced to explain the benefits of magnesium including it's effects on platelets and haemostasis. However, few studies have analysed such a relationship in humans. This project was designed to assess the effect of bolus magnesium infusion on ex vivo platelet aggregation and certain haemostatic parameters in healthy volunteers. One gram of magnesium was diluted in 50 ml of D5W and infused over a period of 15 min. The changes of platelet aggregability, plasma antithrombin-III, Protein C, total Protein S, fibronectin, endothelin-1, as well as the metabolites of thromboxane and prostacyclin were determined prior to and immediately after magnesium infusion. Results: Serum magnesium concentration increased from 2.10 ± 0.08 at baseline to 3.12 ± 0.13 mg dl-1 (P = 0.0002) post-infusion. Magnesium infusion was associated with a significant elevation in ADP (+19.3%); ristocetin (+13,6%); and collagen-induced platelet aggregation (+14.2%); an increase in plasma antithrombin-III (+10.3%) and thromboxane (+49.4%) when compared to pre-infusion levels. Against this, total Protein S (-20.7%), Protein C (-11.2%) and ET-1 (-26.3%) plasma concentrations were markedly decreased. There were no significant differences in plasma fibronectin and prostacyclin levels. Contrary to expectations, magnesium infusion in human volunteers is associated with platelet activation and mostly small unfavourable changes in certain haemostatic factors. However, the observed changes were small and for the most part remained within the normal physiologic range.
AB - The purpose of this study was an attempt to extrapolate favorable observations on the effects of magnesium on platelets and haemostasis from animal models to humans. Intravenous magnesium in the treatment of acute myocardial infarction has been tested in several large clinical trials and remains controversial. The mechanism for the cardioprotective properties of magnesium is unknown. Based on experimental studies, several different hypotheses have been advanced to explain the benefits of magnesium including it's effects on platelets and haemostasis. However, few studies have analysed such a relationship in humans. This project was designed to assess the effect of bolus magnesium infusion on ex vivo platelet aggregation and certain haemostatic parameters in healthy volunteers. One gram of magnesium was diluted in 50 ml of D5W and infused over a period of 15 min. The changes of platelet aggregability, plasma antithrombin-III, Protein C, total Protein S, fibronectin, endothelin-1, as well as the metabolites of thromboxane and prostacyclin were determined prior to and immediately after magnesium infusion. Results: Serum magnesium concentration increased from 2.10 ± 0.08 at baseline to 3.12 ± 0.13 mg dl-1 (P = 0.0002) post-infusion. Magnesium infusion was associated with a significant elevation in ADP (+19.3%); ristocetin (+13,6%); and collagen-induced platelet aggregation (+14.2%); an increase in plasma antithrombin-III (+10.3%) and thromboxane (+49.4%) when compared to pre-infusion levels. Against this, total Protein S (-20.7%), Protein C (-11.2%) and ET-1 (-26.3%) plasma concentrations were markedly decreased. There were no significant differences in plasma fibronectin and prostacyclin levels. Contrary to expectations, magnesium infusion in human volunteers is associated with platelet activation and mostly small unfavourable changes in certain haemostatic factors. However, the observed changes were small and for the most part remained within the normal physiologic range.
KW - Antithrombins
KW - Endothelin-1
KW - Fibronectin
KW - Human
KW - Magnesium
KW - Platelets
KW - Prostaglandins
UR - http://www.scopus.com/inward/record.url?scp=0031190347&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031190347&partnerID=8YFLogxK
U2 - 10.1006/phrs.1997.0212
DO - 10.1006/phrs.1997.0212
M3 - Article
C2 - 9368910
AN - SCOPUS:0031190347
SN - 1043-6618
VL - 36
SP - 17
EP - 22
JO - Pharmacological Research
JF - Pharmacological Research
IS - 1
ER -